CPIX (Cumberland Pharmaceuticals) Cyclically Adjusted Revenue per Share: $2.97 (As of Mar. 2026)


CPIX Cumberland Pharmaceuticals Inc CPIX
36 GF Score
Price $7.13
GF Value $2.16
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Cumberland Pharmaceuticals Cyclically Adjusted Revenue per Share?

Cumberland Pharmaceuticals CPIX +10.03% 36 Cyclically Adjusted Revenue per Share is $2.97 as of Mar. 2026. GuruFocus rates CPIX with a GF Score™ of 36/100 and a GF Value™ of $2.16 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Cumberland Pharmaceuticals's adjusted revenue per share for the three months ended in Mar. 2026 was $0.610. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $2.97 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Cumberland Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 3.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 3.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 4.40% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 2.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Cumberland Pharmaceuticals was 5.00% per year. The lowest was -0.10% per year. And the median was 3.50% per year.

As of today (2026-07-02), Cumberland Pharmaceuticals's current stock price is $7.13. Cumberland Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $2.97. Cumberland Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 2.40.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Cumberland Pharmaceuticals was 3.31. The lowest was 0.38. And the median was 1.40.


Cumberland Pharmaceuticals  (NAS:CPIX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Cumberland Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=7.13/2.97
=2.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Cumberland Pharmaceuticals was 3.31. The lowest was 0.38. And the median was 1.40.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Cumberland Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Cumberland Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Cumberland Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cumberland Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Cumberland Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.47 2.60 2.73 2.81 2.92

Cumberland Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.86 2.88 2.89 2.92 2.97

CPIX vs INCR, CTOR, TLPH: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cumberland Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cumberland Pharmaceuticals Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cumberland Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Cumberland Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


CPIX
36GF Score
Cumberland Pharmaceuticals Inc CPIX
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cumberland Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cumberland Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.61/330.2130*330.2130
=0.610

Current CPI (Mar. 2026) = 330.2130.

Cumberland Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.456 241.018 0.625
201609 0.533 241.428 0.729
201612 0.563 241.432 0.770
201703 0.601 243.801 0.814
201706 0.541 244.955 0.729
201709 0.706 246.819 0.945
201712 0.741 246.524 0.993
201803 0.547 249.554 0.724
201806 0.648 251.989 0.849
201809 0.545 252.439 0.713
201812 0.135 251.233 0.177
201903 0.549 254.202 0.713
201906 0.607 256.143 0.783
201909 0.451 256.759 0.580
201912 0.611 256.974 0.785
202003 0.535 258.115 0.684
202006 0.630 257.797 0.807
202009 0.611 260.280 0.775
202012 0.683 260.474 0.866
202103 0.691 264.877 0.861
202106 0.599 271.696 0.728
202109 0.543 274.310 0.654
202112 0.562 278.802 0.666
202203 0.761 287.504 0.874
202206 0.701 296.311 0.781
202209 0.788 296.808 0.877
202212 0.634 296.797 0.705
202303 0.632 301.836 0.691
202306 0.748 305.109 0.810
202309 0.706 307.789 0.757
202312 0.660 306.746 0.710
202403 0.603 312.332 0.638
202406 0.698 314.175 0.734
202409 0.647 315.301 0.678
202412 0.747 315.605 0.782
202503 0.768 319.799 0.793
202506 0.724 322.561 0.741
202509 0.554 324.800 0.563
202512 0.940 324.054 0.958
202603 0.610 330.213 0.610

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $2.97 mean?
Cumberland Pharmaceuticals (CPIX) has a Cyclically Adjusted Revenue per Share of $2.97 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Cumberland Pharmaceuticals and its competitors.
Is Cumberland Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Cumberland Pharmaceuticals' current Cyclically Adjusted Revenue per Share is $2.97. Overall, Cumberland Pharmaceuticals has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cumberland Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to INCR and CTOR?
Cumberland Pharmaceuticals' Cyclically Adjusted Revenue per Share of $2.97 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Cumberland Pharmaceuticals and its competitors. Cumberland Pharmaceuticals's current Cyclically Adjusted Revenue per Share is $2.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cumberland Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Cumberland Pharmaceuticals (CPIX) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.16, compared to a current price of $7.13 — trading 230.1% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $2.97. Cumberland Pharmaceuticals' overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Cumberland Pharmaceuticals (CPIX), the current Cyclically Adjusted Revenue per Share is $2.97 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cumberland Pharmaceuticals (CPIX) Overvalued in 2026?

Based on GuruFocus' analysis, Cumberland Pharmaceuticals stock appears to be overvalued. The current stock price of $7.13 is trading 230.1% above its estimated GF Value™ of $2.16. GuruFocus considers Cumberland Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for CPIX:

  • Cyclically Adjusted Revenue per Share: $2.97
  • GF Value™: $2.16 vs. price of $7.13 (230.1% above fair value)
  • GF Score™: 36/100 with 5 warning signs

No single metric tells the full story. See the CPIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cumberland Pharmaceuticals Business Description

Address 1600 West End Avenue, Suite 1300, Nashville, TN, USA, 37203
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment, which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The firm promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. Its brands include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Geographically, the company generates revenue from China, South Korea, Russia, Mexico, Australia, and Saudi Arabia.
36GF Score

Get the complete analysis for CPIX

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.13
Price
$2.16
GF Value